ID   ZA
AC   CVCL_D596
DR   cancercelllines; CVCL_D596
DR   CGH-DB; 361-2
DR   Cosmic; 930337
DR   Cosmic; 1046039
DR   Cosmic; 1123029
DR   IARC_TP53; 1108
DR   Wikidata; Q54995865
RX   PubMed=1570156;
RX   PubMed=2228902;
RX   PubMed=2654810;
RX   PubMed=10069537;
RX   PubMed=12632084;
RX   PubMed=17052259;
RX   PubMed=17599052;
RX   PubMed=18097548;
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000035554; Zygosity=Unspecified (PubMed=2654810).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly279Glu (c.836G>A); ClinVar=VCV000419454; Zygosity=Unspecified (PubMed=1570156).
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
DI   NCIt; C4833; Oral cavity squamous cell carcinoma
DI   ORDO; Orphanet_502363; Squamous cell carcinoma of the oral cavity
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   76Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 19-12-24; Version: 20
//
RX   PubMed=1570156;
RA   Sakai E., Tsuchida N.;
RT   "Most human squamous cell carcinomas in the oral cavity contain
RT   mutated p53 tumor-suppressor genes.";
RL   Oncogene 7:927-933(1992).
//
RX   PubMed=2228902; DOI=10.1007/BF02624609;
RA   Rikimaru K., Toda H., Tachikawa N., Kamata N., Enomoto S.;
RT   "Growth of the malignant and nonmalignant human squamous cells in a
RT   protein-free defined medium.";
RL   In Vitro Cell. Dev. Biol. 26:849-856(1990).
//
RX   PubMed=2654810;
RA   Tadokoro K., Ueda M., Ohshima T., Fujita K., Rikimaru K.,
RA   Takahashi N., Enomoto S., Tsuchida N.;
RT   "Activation of oncogenes in human oral cancer cells: a novel codon 13
RT   mutation of c-H-ras-1 and concurrent amplifications of c-erbB-1 and c-myc.";
RL   Oncogene 4:499-505(1989).
//
RX   PubMed=10069537; DOI=10.1111/j.1600-0714.1999.tb02006.x;
RA   Hoteiya T., Hayashi E., Satomura K., Kamata N., Nagayama M.;
RT   "Expression of E-cadherin in oral cancer cell lines and its
RT   relationship to invasiveness in SCID mice in vivo.";
RL   J. Oral Pathol. Med. 28:107-111(1999).
//
RX   PubMed=12632084; DOI=10.3892/ijo.22.4.891;
RA   Yokoyama K., Kamata N., Fujimoto R., Tsutsumi S., Tomonari M.,
RA   Taki M., Hosokawa H., Nagayama M.;
RT   "Increased invasion and matrix metalloproteinase-2 expression by
RT   Snail-induced mesenchymal transition in squamous cell carcinomas.";
RL   Int. J. Oncol. 22:891-898(2003).
//
RX   PubMed=17052259; DOI=10.1111/j.1349-7006.2006.00343.x; PMCID=PMC11160012;
RA   Kozaki K.-i., Imoto I., Pimkhaokham A., Hasegawa S., Tsuda H.,
RA   Omura K., Inazawa J.;
RT   "PIK3CA mutation is an oncogenic aberration at advanced stages of oral
RT   squamous cell carcinoma.";
RL   Cancer Sci. 97:1351-1358(2006).
//
RX   PubMed=17599052; DOI=10.1038/sj.onc.1210589;
RA   Suzuki E., Imoto I., Pimkhaokham A., Nakagawa T., Kamata N.,
RA   Kozaki K.-i., Amagasa T., Inazawa J.;
RT   "PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in
RT   oral squamous-cell carcinomas by aberrant promoter hypermethylation.";
RL   Oncogene 26:7921-7932(2007).
//
RX   PubMed=18097548; DOI=10.3892/ijo.32.1.101;
RA   Murugan A.K., Hong N.T., Fukui Y., Munirajan A.K., Tsuchida N.;
RT   "Oncogenic mutations of the PIK3CA gene in head and neck squamous cell
RT   carcinomas.";
RL   Int. J. Oncol. 32:101-111(2008).
//